Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301


Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

López-Fauqued M, Campora L, Delannois F, El Idrissi M, Oostvogels L, De Looze FJ, Diez-Domingo J, Heineman TC, Lal H, McElhaney JE, McNeil SA, Yeo W, Tavares-Da-Silva F; ZOE-50/70 Study Group.

Vaccine. 2019 Apr 24;37(18):2482-2493. doi: 10.1016/j.vaccine.2019.03.043. Epub 2019 Mar 29.


Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design.

Truong NR, Smith JB, Sandgren KJ, Cunningham AL.

Front Immunol. 2019 Mar 6;10:373. doi: 10.3389/fimmu.2019.00373. eCollection 2019. Review.


Protocol for faecal microbiota transplantation in ulcerative colitis (FMTUC): a randomised feasibility study.

Jitsumura M, Cunningham AL, Hitchings MD, Islam S, Davies AP, Row PE, Riddell AD, Kinross J, Wilkinson TS, Jenkins GJ, Williams JG, Harris DA.

BMJ Open. 2018 Oct 18;8(10):e021987. doi: 10.1136/bmjopen-2018-021987.


Murine skin-resident γδT cells impair the immune response to HSV in skin.

Fernandez MA, Yu U, Ferguson AL, Wang D, Francis E, Roediger B, Weninger W, Cantrill LC, Cunningham AL, Alexander SI, Jones CA.

Infect Disord Drug Targets. 2018 Oct 1. doi: 10.2174/1871526518666181001123816. [Epub ahead of print]


Herpes Zoster Vaccines.

Cunningham AL, Levin MJ.

J Infect Dis. 2018 Sep 22;218(suppl_2):S127-S133. doi: 10.1093/infdis/jiy382.


Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older.

Cunningham AL, Heineman TC, Lal H, Godeaux O, Chlibek R, Hwang SJ, McElhaney JE, Vesikari T, Andrews C, Choi WS, Esen M, Ikematsu H, Choma MK, Pauksens K, Ravault S, Salaun B, Schwarz TF, Smetana J, Abeele CV, Van den Steen P, Vastiau I, Weckx LY, Levin MJ; ZOE-50/70 Study Group.

J Infect Dis. 2018 May 5;217(11):1750-1760. doi: 10.1093/infdis/jiy095.


Infection and Transport of Herpes Simplex Virus Type 1 in Neurons: Role of the Cytoskeleton.

Miranda-Saksena M, Denes CE, Diefenbach RJ, Cunningham AL.

Viruses. 2018 Feb 23;10(2). pii: E92. doi: 10.3390/v10020092. Review.


Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Kovac M, Lal H, Cunningham AL, Levin MJ, Johnson RW, Campora L, Volpi A, Heineman TC; ZOE-50/70 Study Group.

Vaccine. 2018 Mar 14;36(12):1537-1541. doi: 10.1016/j.vaccine.2018.02.029. Epub 2018 Feb 17.


Cytoskeletons in the Closet-Subversion in Alphaherpesvirus Infections.

Denes CE, Miranda-Saksena M, Cunningham AL, Diefenbach RJ.

Viruses. 2018 Feb 13;10(2). pii: E79. doi: 10.3390/v10020079. Review.


Exploring the Antimicrobial Action of Quaternary Amines against Acinetobacter baumannii.

Knauf GA, Cunningham AL, Kazi MI, Riddington IM, Crofts AA, Cattoir V, Trent MS, Davies BW.

MBio. 2018 Feb 6;9(1). pii: e02394-17. doi: 10.1128/mBio.02394-17.


Deletion of the Major Facilitator Superfamily Transporter fptB Alters Host Cell Interactions and Attenuates Virulence of Type A Francisella tularensis.

Balzano PM, Cunningham AL, Grassel C, Barry EM.

Infect Immun. 2018 Feb 20;86(3). pii: e00832-17. doi: 10.1128/IAI.00832-17. Print 2018 Mar.


Discovery of Next-Generation Antimicrobials through Bacterial Self-Screening of Surface-Displayed Peptide Libraries.

Tucker AT, Leonard SP, DuBois CD, Knauf GA, Cunningham AL, Wilke CO, Trent MS, Davies BW.

Cell. 2018 Jan 25;172(3):618-628.e13. doi: 10.1016/j.cell.2017.12.009. Epub 2018 Jan 4.


Dendritic cells in the cornea during Herpes simplex viral infection and inflammation.

Kwon MS, Carnt NA, Truong NR, Pattamatta U, White AJ, Samarawickrama C, Cunningham AL.

Surv Ophthalmol. 2018 Jul - Aug;63(4):565-578. doi: 10.1016/j.survophthal.2017.11.001. Epub 2017 Nov 10. Review.


Antimicrobial Peptides of Marine Crustaceans: The Potential and Challenges of Developing Therapeutic Agents.

Zanjani NT, Miranda-Saksena M, Cunningham AL, Dehghani F.

Curr Med Chem. 2018;25(19):2245-2259. doi: 10.2174/0929867324666171106155936. Review.


Mechanism of Interferon-Stimulated Gene Induction in HIV-1-Infected Macrophages.

Nasr N, Alshehri AA, Wright TK, Shahid M, Heiner BM, Harman AN, Botting RA, Helbig KJ, Beard MR, Suzuki K, Kelleher AD, Hertzog P, Cunningham AL.

J Virol. 2017 Sep 27;91(20). pii: e00744-17. doi: 10.1128/JVI.00744-17. Print 2017 Oct 15.


Vaccine profile of herpes zoster (HZ/su) subunit vaccine.

Cunningham AL, Heineman T.

Expert Rev Vaccines. 2017 Jul;16(7):1-10. doi: 10.1080/14760584.2017.1329012. Epub 2017 May 19. Review.


From Ocean to Bedside: the Therapeutic Potential of Molluscan Hemocyanins.

Zanjani NT, Saksena MM, Dehghani F, Cunningham AL.

Curr Med Chem. 2018;25(20):2292-2303. doi: 10.2174/0929867324666170502124227. Review.


Phenotypic and functional consequences of different isolation protocols on skin mononuclear phagocytes.

Botting RA, Bertram KM, Baharlou H, Sandgren KJ, Fletcher J, Rhodes JW, Rana H, Plasto TM, Wang XM, Lim JJK, Barnouti L, Kohout MP, Papadopoulos T, Merten S, Olbourne N, Cunningham AL, Haniffa M, Harman AN.

J Leukoc Biol. 2017 Jun;101(6):1393-1403. doi: 10.1189/jlb.4A1116-496R. Epub 2017 Mar 7.


Langerhans cells and sexual transmission of HIV and HSV.

Botting RA, Rana H, Bertram KM, Rhodes JW, Baharlou H, Nasr N, Cunningham AL, Harman AN.

Rev Med Virol. 2017 Mar;27(2). doi: 10.1002/rmv.1923. Epub 2017 Jan 3. Review.


Vaccine provision: Delivering sustained & widespread use.

Preiss S, Garçon N, Cunningham AL, Strugnell R, Friedland LR.

Vaccine. 2016 Dec 20;34(52):6665-6671. doi: 10.1016/j.vaccine.2016.10.079. Epub 2016 Nov 22. Review.


Vaccination of special populations: Protecting the vulnerable.

Doherty M, Schmidt-Ott R, Santos JI, Stanberry LR, Hofstetter AM, Rosenthal SL, Cunningham AL.

Vaccine. 2016 Dec 20;34(52):6681-6690. doi: 10.1016/j.vaccine.2016.11.015. Epub 2016 Nov 18. Review.


Vaccine development: From concept to early clinical testing.

Cunningham AL, Garçon N, Leo O, Friedland LR, Strugnell R, Laupèze B, Doherty M, Stern P.

Vaccine. 2016 Dec 20;34(52):6655-6664. doi: 10.1016/j.vaccine.2016.10.016. Epub 2016 Oct 18. Review.


Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Cunningham AL, Lal H, Kovac M, Chlibek R, Hwang SJ, Díez-Domingo J, Godeaux O, Levin MJ, McElhaney JE, Puig-Barberà J, Vanden Abeele C, Vesikari T, Watanabe D, Zahaf T, Ahonen A, Athan E, Barba-Gomez JF, Campora L, de Looze F, Downey HJ, Ghesquiere W, Gorfinkel I, Korhonen T, Leung E, McNeil SA, Oostvogels L, Rombo L, Smetana J, Weckx L, Yeo W, Heineman TC; ZOE-70 Study Group.

N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800.


Understanding natural herpes simplex virus immunity to inform next-generation vaccine design.

Sandgren KJ, Bertram K, Cunningham AL.

Clin Transl Immunology. 2016 Jul 29;5(7):e94. doi: 10.1038/cti.2016.44. eCollection 2016 Jul. Review.


M-Cells Contribute to the Entry of an Oral Vaccine but Are Not Essential for the Subsequent Induction of Protective Immunity against Francisella tularensis.

Cunningham AL, Guentzel MN, Yu JJ, Hung CY, Forsthuber TG, Navara CS, Yagita H, Williams IR, Klose KE, Eaves-Pyles TD, Arulanandam BP.

PLoS One. 2016 Apr 21;11(4):e0153402. doi: 10.1371/journal.pone.0153402. eCollection 2016.


The herpes zoster subunit vaccine.

Cunningham AL.

Expert Opin Biol Ther. 2016;16(2):265-71. doi: 10.1517/14712598.2016.1134481. Review.


Fast track, dynein-dependent nuclear targeting of human immunodeficiency virus Vpr protein; impaired trafficking in a clinical isolate.

Caly L, Kassouf VT, Moseley GW, Diefenbach RJ, Cunningham AL, Jans DA.

Biochem Biophys Res Commun. 2016 Feb 12;470(3):735-740. doi: 10.1016/j.bbrc.2016.01.051. Epub 2016 Jan 11.


Dual Role of Herpes Simplex Virus 1 pUS9 in Virus Anterograde Axonal Transport and Final Assembly in Growth Cones in Distal Axons.

Miranda-Saksena M, Boadle RA, Diefenbach RJ, Cunningham AL.

J Virol. 2015 Dec 23;90(5):2653-63. doi: 10.1128/JVI.03023-15.


The Basic Domain of Herpes Simplex Virus 1 pUS9 Recruits Kinesin-1 To Facilitate Egress from Neurons.

Diefenbach RJ, Davis A, Miranda-Saksena M, Fernandez MA, Kelly BJ, Jones CA, LaVail JH, Xue J, Lai J, Cunningham AL.

J Virol. 2015 Dec 9;90(4):2102-11. doi: 10.1128/JVI.03041-15. Print 2016 Feb 15.


Abalone Hemocyanin Blocks the Entry of Herpes Simplex Virus 1 into Cells: a Potential New Antiviral Strategy.

Talaei Zanjani N, Miranda-Saksena M, Valtchev P, Diefenbach RJ, Hueston L, Diefenbach E, Sairi F, Gomes VG, Cunningham AL, Dehghani F.

Antimicrob Agents Chemother. 2015 Dec 7;60(2):1003-12. doi: 10.1128/AAC.01738-15. Print 2016 Feb.


The C-type Lectin Langerin Functions as a Receptor for Attachment and Infectious Entry of Influenza A Virus.

Ng WC, Londrigan SL, Nasr N, Cunningham AL, Turville S, Brooks AG, Reading PC.

J Virol. 2015 Oct 14;90(1):206-21. doi: 10.1128/JVI.01447-15. Print 2016 Jan 1.


Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.

Lal H, Cunningham AL, Heineman TC.

N Engl J Med. 2015 Oct 15;373(16):1576-7. doi: 10.1056/NEJMc1508392. No abstract available.


Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.

Santiago AE, Mann BJ, Qin A, Cunningham AL, Cole LE, Grassel C, Vogel SN, Levine MM, Barry EM.

Pathog Dis. 2015 Aug;73(6):ftv036. doi: 10.1093/femspd/ftv036. Epub 2015 May 17.


Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, Levin MJ, McElhaney JE, Poder A, Puig-Barberà J, Vesikari T, Watanabe D, Weckx L, Zahaf T, Heineman TC; ZOE-50 Study Group.

N Engl J Med. 2015 May 28;372(22):2087-96. doi: 10.1056/NEJMoa1501184. Epub 2015 Apr 28.


Relay of herpes simplex virus between Langerhans cells and dermal dendritic cells in human skin.

Kim M, Truong NR, James V, Bosnjak L, Sandgren KJ, Harman AN, Nasr N, Bertram KM, Olbourne N, Sawleshwarkar S, McKinnon K, Cohen RC, Cunningham AL.

PLoS Pathog. 2015 Apr 13;11(4):e1004812. doi: 10.1371/journal.ppat.1004812. eCollection 2015 Apr.


HIV Blocks Interferon Induction in Human Dendritic Cells and Macrophages by Dysregulation of TBK1.

Harman AN, Nasr N, Feetham A, Galoyan A, Alshehri AA, Rambukwelle D, Botting RA, Hiener BM, Diefenbach E, Diefenbach RJ, Kim M, Mansell A, Cunningham AL.

J Virol. 2015 Jul;89(13):6575-84. doi: 10.1128/JVI.00889-15. Epub 2015 Apr 8.


Herpes simplex virus type 2-infected dendritic cells produce TNF-α, which enhances CCR5 expression and stimulates HIV production from adjacent infected cells.

Marsden V, Donaghy H, Bertram KM, Harman AN, Nasr N, Keoshkerian E, Merten S, Lloyd AR, Cunningham AL.

J Immunol. 2015 May 1;194(9):4438-45. doi: 10.4049/jimmunol.1401706. Epub 2015 Apr 3.


Why Australia needs a Medical Research Future Fund.

Cunningham AL, Anderson T, Bennett CC, Crabb BS, Goodier G, Hilton D, Koff E, Trapani J.

Med J Aust. 2015 Feb 16;202(3):123-4. No abstract available.


Live attenuated Francisella novicida vaccine protects against Francisella tularensis pulmonary challenge in rats and non-human primates.

Chu P, Cunningham AL, Yu JJ, Nguyen JQ, Barker JR, Lyons CR, Wilder J, Valderas M, Sherwood RL, Arulanandam BP, Klose KE.

PLoS Pathog. 2014 Oct 23;10(10):e1004439. doi: 10.1371/journal.ppat.1004439. eCollection 2014 Oct.


Inhibition of two temporal phases of HIV-1 transfer from primary Langerhans cells to T cells: the role of langerin.

Nasr N, Lai J, Botting RA, Mercier SK, Harman AN, Kim M, Turville S, Center RJ, Domagala T, Gorry PR, Olbourne N, Cunningham AL.

J Immunol. 2014 Sep 1;193(5):2554-64. doi: 10.4049/jimmunol.1400630. Epub 2014 Jul 28.


Enhancement of vaccine efficacy by expression of a TLR5 ligand in the defined live attenuated Francisella tularensis subsp. novicida strain U112ΔiglB::fljB.

Cunningham AL, Dang KM, Yu JJ, Guentzel MN, Heidner HW, Klose KE, Arulanandam BP.

Vaccine. 2014 Sep 8;32(40):5234-40. doi: 10.1016/j.vaccine.2014.07.038. Epub 2014 Jul 19.


Preparation of herpes simplex virus-infected primary neurons for transmission electron microscopy.

Miranda-Saksena M, Boadle R, Cunningham AL.

Methods Mol Biol. 2014;1144:223-34. doi: 10.1007/978-1-4939-0428-0_15.


Immunisation for herpes zoster: current status.

Cunningham AL, Litt JC, Macintyre CR.

Med J Aust. 2014 Mar 17;200(5):243-4. No abstract available.


Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia.

Steain M, Sutherland JP, Rodriguez M, Cunningham AL, Slobedman B, Abendroth A.

J Virol. 2014 Mar;88(5):2704-16. doi: 10.1128/JVI.03445-13. Epub 2013 Dec 18.


HSV-2 incidence by sex over four age periods to age 38 in a birth cohort.

Dickson N, Righarts A, van Roode T, Paul C, Taylor J, Cunningham AL.

Sex Transm Infect. 2014 May;90(3):243-5. doi: 10.1136/sextrans-2013-051235. Epub 2013 Dec 13.


Formulation of abalone hemocyanin with high antiviral activity and stability.

Zanjani NT, Sairi F, Marshall G, Saksena MM, Valtchev P, Gomes VG, Cunningham AL, Dehghani F.

Eur J Pharm Sci. 2014 Mar 12;53:77-85. doi: 10.1016/j.ejps.2013.11.013. Epub 2013 Nov 23.


The microvesicle component of HIV-1 inocula modulates dendritic cell infection and maturation and enhances adhesion to and activation of T lymphocytes.

Mercier SK, Donaghy H, Botting RA, Turville SG, Harman AN, Nasr N, Ji H, Kusebauch U, Mendoza L, Shteynberg D, Sandgren K, Simpson RJ, Moritz RL, Cunningham AL.

PLoS Pathog. 2013 Oct;9(10):e1003700. doi: 10.1371/journal.ppat.1003700. Epub 2013 Oct 17. Erratum in: PLoS Pathog. 2013 Oct;9(10). doi: 10.1371/annotation/059beb14-db84-4836-9fef-ec351946025a.


Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.

Wightman F, Lu HK, Solomon AE, Saleh S, Harman AN, Cunningham AL, Gray L, Churchill M, Cameron PU, Dear AE, Lewin SR.

AIDS. 2013 Nov 28;27(18):2853-62. doi: 10.1097/QAD.0000000000000067.


HIV infection of dendritic cells.

Nasr N, Harman A, Turville S, Cunningham AL.

Methods Mol Biol. 2014;1087:221-32. doi: 10.1007/978-1-62703-670-2_18.


Safety and immunogenicity of a glycoprotein D genital herpes vaccine in healthy girls 10-17 years of age: results from a randomised, controlled, double-blind trial.

HSV-040 Study Group, Abu-Elyazeed RR, Heineman T, Dubin G, Fourneau M, Leroux-Roels I, Leroux-Roels G, Richardus JH, Ostergaard L, Diez-Domingo J, Poder A, Van Damme P, Romanowski B, Blatter M, Silfverdal SA, Berglund J, Josefsson A, Cunningham AL, Flodmark CE, Tragiannidis A, Dobson S, Olafsson J, Puig-Barbera J, Mendez M, Barton S, Bernstein D, Mares J, Ratner P.

Vaccine. 2013 Dec 9;31(51):6136-43. doi: 10.1016/j.vaccine.2013.06.081. Epub 2013 Jul 9.


Supplemental Content

Loading ...
Support Center